NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This pilot clinical trial studies combined fluorine F 18 sodium fluoride (NaF)/ fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and magnetic resonance imaging (MRI) in measuring response to a drug, radium Ra 223 dichloride (Ra-223), in treating patients with prostate cancer that has not responded to hormone therapy and has spread to other parts of the body. Combining NaF/FDG in a simultaneous PET/MRI scan may help doctors accurately measure how well patients respond to treatment with radium Ra 223 dichloride.

Official Title

Combined "One Stop Shop" NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: Male
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Provides written informed consent - Diagnosed with mCRPC and painful bone metastases, referred for Xofigo (radium Ra 223 dichloride) - Able to remain still for duration of the imaging procedure (about one hour)
Exclusion Criteria:
  1. - Metallic implants


Andrei Iagaru
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Sandy Srinivas
Sandy Srinivas
Medical oncologist, Urologic specialist, Genitourinary specialist
Professor of Medicine (Oncology) and, by courtesy, of Urology

Contact us to find out if this trial is right for you.


Omar Rutledge